RNA vaccines
A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.
1. A method for inducing a TH1-biased immune response in a subject, comprising administering to the subject a composition comprising: an RNA molecule and an adjuvant comprising one or more cytokine, wherein the RNA molecule encodes an allergen selected from the group consisting of Aln g 1, Alt a 1, Amb a 1, Api g 1, Ara h 2, Bet v 1, beta-casein, Car b 1, Cas s 1, Cla h 8, Cor a 1, Cry j 1, Cyp c 1, Dau c 1, Der p 2, Fag s 1, Fel d 1, Hey b 6, Jun a 1, Mal d 1, ovalbumin (OVA), Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, and hypoallergenic fragments thereof, and wherein the RNA molecule optionally further has an RNA sequence encoding a peptide, polypeptide or protein and/or at least one element selected from the group consisting of replicase, 1-globin leader sequence, cap0, cap1 and poly A tail and the one or more cytokine is selected from the group consisting of IL-2, IL-3, IL-12, IL-15, IL-18, IFN-gamma, IL-10, TGF-beta, granulocyte-macrophage (GM)-colony stimulating factor (CSF) and macrophage inflammatory factor.
2. The method according to claim 1 , comprising administering the composition by intramuscular, intradermal, intravenous, transdermal, topical or biolistic route.
3. The method according to claim 1 , wherein the composition consists of the RNA molecule, water and one or more cytokine selected from the group consisting of IL-2, IL-3, IL-12, IL-15, IL-18, IFN-gamma, IL-10, TGF-beta, granulocyte-macrophage (GM)-colony stimulating factor (CSF) and macrophage inflammatory factor.
4. The method according to claim 1 , wherein the RNA molecule encoding the allergen further has an RNA sequence encoding a peptide, polypeptide or protein.
5. The method according to claim 1 , wherein the RNA molecule further has at least one element selected from the group consisting of replicase, 1-globin leader sequence, cap0, cap1 and poly A tail.
6. The method according to claim 1 , wherein said cytokine is IL-12.
7. The method according to claim 1 , wherein said cytokine is IL-15.
8. A method for inducing a TH1-biased immune response in a subject, comprising administering to the subject a composition comprising an RNA molecule suspended in water and an adjuvant comprising one or more cytokine, wherein the RNA molecule encodes an allergen selected from the group consisting of Aln g 1, Alt a 1, Amb a 1, Api g 1, Ara h 2, Bet v 1, beta-casein, Car b 1, Cas s 1, Cla h 8, Cor a 1, Cry j 1, Cyp c 1, Dau c 1, Der p 2, Fag s 1, Fel d 1, Hey b 6, Jun a 1, Mal d 1, ovalbumin (OVA), Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, hypoallergenic fragments thereof, wherein the RNA molecule optionally further has an RNA sequence encoding a peptide, polypeptide or protein and/or at least one element selected from the group consisting of replicase, 1-globin leader sequence, cap0, cap1 and poly A tail, wherein said one or more cytokine is selected from the group consisting of IL-2, IL-3, IL-12, IL-15, IL-18, IFN-gamma, IL-10, TGF-beta, granulocyte-macrophage (GM)-colony stimulating factor (CSF) and macrophage inflammatory factor, and wherein administering the composition induces in the subject the TH1-biased immune response.
9. The method according to claim 8 , comprising administering the composition by intramuscular, intradermal, intravenous, transdermal, topical or biolistic route.
10. The method according to claim 8 , wherein the composition consists of the RNA molecule, water and one or more cytokine selected from the group consisting of IL-2, IL-3, IL-12, IL-15, IL-18, IFN-gamma, IL-10, TGF-beta, granulocyte-macrophage (GM)-colony stimulating factor (CSF) and macrophage inflammatory factor.
11. The method according to claim 8 , wherein the RNA molecule encodes the allergen and a peptide, polypeptide or protein.
12. The method according to claim 8 , wherein the RNA molecule has at least one element selected from the group consisting of replicase, 1-globin leader sequence, cap0, cap1 and poly A tail.
13. The method according to claim 8 , wherein said cytokine is IL-12.
14. The method according to claim 8 , wherein said cytokine is IL-15.